Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Decentralized perp futures exchange Hyperliquid has changed the game for airdrops, handing out the largest airdrop in the ...

Finbold has selected three interesting pharmaceutical stocks that could see significant moves to the upside in 2025.

About four years after launch, Orna Therapeutics Inc. signed its second major deal, this time validating the lipid nanoparticle delivery technology it acquired through its Renagade Therapeutics Inc.

Vertex Pharmaceuticals Inc. closed $111.56 below its 52-week high ($519.88), which the company achieved on November 8th.

HBS, CDW, Leidos, SAP, SAS and Vertex are among the companies to list open positions for channel-related roles.

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Vertex VERX shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

New research by Security Intelligence has revealed security risks in MLOps platforms including Azure ML, BigML and Google ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...